NEOCD64: Neutrophil CD64 for Early Diagnosis of Nosocomial Infection in Preterm Newborns

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Unknown status
CT.gov ID
NCT01951781
Collaborator
(none)
153
1
1
29
5.3

Study Details

Study Description

Brief Summary

Diagnosis of late-onset sepsis is difficult in the absence of specific clinical signs and biological markers in the infection initial phase .The aim of this study is to determine the performance of a new infection marker : Neutrophil CD64 for early diagnosis in nosocomial infection (NI) in preterm newborns.

METHODS :
  • Monocentric prospective study including preterm newborn infants (<37 weeks of gestationnal age ) with clinical suspicion of nosocomial infection in a neonatal intensice care unit (Neonatal intensive care unit of Montpellier, France).

  • Patients will be enrolled in the study after informed consents. Rapid and automated CD64 measurment will be realized during the conventional blood sample including C-Reactive Protein (CRP), Procalcitonin (PCT) and blood culture.

  • Broad-spectrum antibiotic therapy can be started on the advice of clinician and blinded the result of CD64. Patients will be then classed in three groups using CDC criteria (center for disease control) : 1-no infection, 2-infection, 3-possible infection during the multidisciplinary staff. Specificity, sensitivity, negative and positive value of CD64 will be calculated and the performances of CRP, PCT and CD64 will be compared.

153 patients are needed in the study enrolled during a period of 12 months.

PERSPECTIVES Neutrophil CD64 monitoring might be help clinicians to manage nosocomial infections in neonates.CD64 allow to integrate in a decision algorithm with the determination of the best cut-off value to faster processing nosocomial infections and could help to reduce unnecessary antibioc therapy. A rapid technique for determination of CD64 should be readily available in our unit.

Condition or Disease Intervention/Treatment Phase
  • Other: blood sample
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
153 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Diagnostic
Official Title:
Rapid Quantitative Neutrophil CD64 Measurement for Early Diagnosis of Nosocomial Infection in Preterm Newborns
Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Jun 1, 2014
Anticipated Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Other: NEOCD64

NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)

Other: blood sample
blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm) When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood.

Outcome Measures

Primary Outcome Measures

  1. proportion of negatives (healthy patient) which are correctly identified as such [day 1]

Secondary Outcome Measures

  1. proportion of positives (sikness)which are correctly defined as such [day 1]

    sensibility of CD64 value

  2. negative predictive CD64 value [day 1]

  3. positive predictiveCD64 value [day 1]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 5 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • preterm newborn (<37 weeks of gestationnal age )

  • undergoing symptoms of late-onset-sepsis

  • written informed consent obtained from the parents

Exclusion Criteria:
  • patient undergoing antibiotic therapy

  • patient undergoing surgery in the last seven days,

  • patient with severe congenital malformation

  • necrotizing enterocolitis

  • parents unable to understand the purpose of the study

  • no affiliation to social security

Contacts and Locations

Locations

Site City State Country Postal Code
1 Montpellier University hospital Montpellier France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier

Investigators

  • Principal Investigator: Gilles CAMBONIE, Professor, Montpellier hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT01951781
Other Study ID Numbers:
  • 9117
First Posted:
Sep 27, 2013
Last Update Posted:
Jan 9, 2015
Last Verified:
Sep 1, 2013
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2015